Subgroup analysis of randomized clinical trials appears to indicate that abciximab provides substantial benefits in terms of reduced repeat revasculariza-tion and mortality among diabetic patients, with comparable effects observed with tirofiban. Clinical trial evidence with bivalirudin supports similar con clusions. In the REPLACE-2 study of bivalirudin and provisional GP IIb/IIIa inhibition compared with heparin and GP IIb/IIIa inhibition, bivalirudin-treated diabetic patients experienced a lower, but nonsignificant rate of mortality at 12 months (2.3% versus 3.9%, P = NS). No difference in the rate of 30-day bleeding and ischemic outcomes was observed.57 Although the long-term effects of enoxaparin-based strategies in diabetic patients have not been reported, a substantial rate of concomitant GP IIb/IIIa use in these studies will limit the interpretation of these data.

Delicious Diabetic Recipes

Delicious Diabetic Recipes

This brilliant guide will teach you how to cook all those delicious recipes for people who have diabetes.

Get My Free Ebook

Post a comment